News

Switching From Reference Trastuzumab to Biosimilar for HER2 Positive Breast Cancer May Not Affect Infusion Reaction, Cardiac Dysfunction

07/10/2023

Gina Tomaine ;

Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.

Switching from reference...

07/10/2023

Oncology

News

Bevacizumab Biosimilar Demonstrates Efficacy, Acceptable Toxicity Compared to Reference Bevacizumab for Patients With Locally Advanced and Advanced NSCLC

06/16/2023

Gina Tomaine ;

Bevacizumab biosimilar demonstrated comparable efficacy to reference bevacizumab among patients with locally advanced and advanced non-small-cell lung cancer, with an acceptable toxicity profile, according to a retrospective study.

Bevacizumab biosimilar...

06/16/2023

Oncology

News

Filgrastim Biosimilar Demonstrated Comparable Efficacy to Originator Filgrastim in Peripheral Blood CD34+ Stem Cell Mobilization Among Patients With Hematologic Malignancies

05/25/2023

Jordan Kadish ;

A filgrastim biosimilar had similar efficacy in peripheral blood CD34+ stem cell mobilization for both autologous and allogeneic stem cell transplantation compared to the referent among patients with hematologic malignancies.

A filgrastim biosimilar had...

05/25/2023

Oncology

News

Pegfilgrastim and Biosimilar Yielded Promising Efficacy, Safety Among Patients With MM Post-AlloSCT

05/24/2023

Jordan Kadish ;

Pegfilgrastim and a pegfilgrastim biosimilar yielded more promising efficacy and safety results than a filgrastim biosimilar among patients with multiple myeloma who had undergone autologous stem cell transplantation.

Pegfilgrastim and a...

05/24/2023

Oncology

News

New Version of Bevacizumab Biosimilar Found Bioequivalent to Referent

05/23/2023

Allison Casey ;

In a phase 1 trial, a new iteration of the MB02 bevacizumab biosimilar was also found to be bioequivalent to the reference bevacizumab.

In a phase 1 trial, a new...

05/23/2023

Oncology

News

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

05/19/2023

Derek Cowsert ;

The TROIKA trial demonstrated comparable efficacy between HD201 and referent trastuzumab for the neoadjuvant treatment of HER2-positive breast cancer.

The TROIKA trial demonstrated...

05/19/2023

Oncology

News

No Difference in Risk of Febrile Neutropenia Between Patients Receiving Pegfilgrastim Biosimilar vs Originator

05/16/2023

Jordan Kadish ;

According to findings from a real-world cohort study, no difference in the risk of febrile neutropenia was observed between patients who received biosimilar pegfilgrastim vs originator pegfilgrastim.

According to findings from a...

05/16/2023

Oncology

News

05/12/2023

Jordan Kadish ;

According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.

According to findings from a...

05/12/2023

Oncology

News

No Association Observed Between Biosimilar Rituximab Exposure and Hypersensitivity Hospitalization

05/12/2023

Jordan Kadish ;

According to findings from a 2-cohort study, exposure to biosimilar rituximab at initiation, switch, or over time was not associated with hospitalization due to hypersensitivity, compared to originator rituximab.

According to findings from a...

05/12/2023

Oncology

News

Cardiac Safety of SB3 Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

05/09/2023

Allison Casey ;

In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.

In a phase 3 trial, the SB3...

05/09/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology